<DOC>
	<DOCNO>NCT01028638</DOCNO>
	<brief_summary>Everolimus indirectly inhibit angiogenesis reduce VEGF production . VEGF non-invasively visualize quantified serial 89Zr-bevacizumab PET imaging patient . The investigator hypothesize decline VEGF early everolimus treatment patient metastatic renal cell carcinoma predict treatment efficacy . 89Zr-bevacizumab PET scan perform baseline , 2 6 week everolimus treatment 14 adult patient metastatic renal cell carcinoma .</brief_summary>
	<brief_title>Vascular Endothelial Growth Factor ( VEGF ) Imaging Before During Everolimus Treatment Renal Cell Carcinoma</brief_title>
	<detailed_description>Background study The majority renal cell carcinoma ( RCC ) characterize profound angiogenesis inactivation Von Hippel Lindau gene . Angiogenesis inhibitor establish first line treatment option metastatic setting . Patients progressive disease treatment angiogenesis inhibitor benefit treatment everolimus , oral mTOR inhibitor result double progression free survival phase III study . Currently possible predict patient benefit treatment mTOR inhibitor . A predictive biomarker efficacy mTOR inhibitor urgently need may spare patient unnecessary side effect , safe cost society mTOR inhibitor expensive agent , may speed research new drug , drug combination drug dosing . One action mTOR inhibitor blockage production vascular endothelial growth factor ( VEGF ) , think primary mechanism responsible antitumor activity RCC . The investigator hypothesize non-invasive measurement VEGF tumour surroundings 89Zr-bevacizumab PET image shortly start everolimus good readout efficacy everolimus patient RCC . Objective study The primary objective study evaluate feasibility 89Zr-bevacizumab PET image biomarker treatment everolimus patient metastatic RCC . 89Zr-bevacizumab PET imaging regard promising biomarker uptake change institution treatment . Study design This pilot study evaluation 89Zr-bevacizumab PET image biomarker treatment everolimus patient mRCC . 89Zr-bevacizumab PET imaging perform start treatment 2 6 week treatment . Study population 14 patient start treatment everolimus metastatic RCC include study . Primary study parameters The primary endpoint change 89Zr-bevacizumab uptake tumor lesion baseline scan scan treatment . Secondary study parameter The secondary endpoint progressive disease accord Response Evaluation Criteria Solid Tumors ( RECIST ) criterion , 3 month treatment . Progression define appearance new disease increase 20 % sum long diameter target lesion . Nature extent burden risk associate participation , benefit group relatedness Patients intravenously inject 3 time point 37MBq result cumulative radiation dose 54 mSv . According ICRP 62 radiation dose fall category III ( moderate risk ) . Life expectancy patient limit incurable renal cell carcinoma , make risk development secondary malignancy clinically likely relevant . Patients pay 3 extra visit hospital tracer injection . PET scan perform regular visit day . Blood sample biomarkers draw routine blood investigation . There direct benefit patient study . If 89Zr-bevacizumab PET image however predictive biomarker angiogenesis inhibitor , many patient spar unnecessary side effect society spar cost futile treatment future .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<criteria>metastatic renal cell cancer Intention start treatment everolimus WHO performance score ≤ 2 measurable disease xray CT scan , least one site disease must unidimensionally measurable follow : Xray &gt; 20 mm Spiral CT scan &gt; 10 mm Nonspiral CT scan &gt; 20 mm ≥ 18 year pregnant nursing woman childbearing potential must use effective contraception absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial patient randomization , write informed consent must give accord GCP , local regulation formulate `` '' `` absence '' inclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>VEGF imaging</keyword>
	<keyword>everolimus</keyword>
	<keyword>renal cell carcinoma</keyword>
	<keyword>PET</keyword>
	<keyword>bevacizumab</keyword>
</DOC>